1. In Vivo
  2. >>Business Strategy

How Much for That Money in the Window?

Cambridge Antibody Technology PLC's January £55 million share-for-share offer for Drug Royalty demonstrates not only CAT's growth in the last decade but also a willingness by biotech companies to indulge in a little creative financing. The move will help CAT reduce its cash burn and ratchet up its R&D spending at a time when the pace of more traditional methods of raising cash remains sluggish. And not least important, the deal illustrates how a transparent financing transaction to improve biotech P&L can be a straightforward alternative to today's obfuscating accounting practices which, in the current climate, look disturbingly Enronian.

If biotech was a TV movie, we'd hear the starlet claim: "I was young. I needed the money." In 1994, a young Cambridge Antibody Technology PLC (CAT) needed the money: it sold 3.5% of future revenues until 2004—falling to 2.5% until 2009—to Canada's Drug Royalty Corp. Inc. for a paltry £1.5 million [See Deal].

Back then, cash was paramount for the UK-based antibody developer. Today, however, a better-funded, maturing CAT is winding its way...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

OS Therapies Eyes Mid 2026 Launch After Breakthrough Osteosarcoma Vaccine Results

 
• By David Wild

New York biotech OS Therapies reported 75% two-year survival in an osteosarcoma trial of its immunotherapy, OST-HER2. Leadership is targeting early 2026 approvals across three continents for what is the first new osteosarcoma treatment in 40 years.

Pharma BD Leaders Navigate Uncertainty And Opportunity

 
• By David Wild

Pharma business development teams are adapting M&A and licensing strategies amid market volatility and looming patent cliffs.

How Biotechs Can Navigate The Capital Crunch

Strategic partnerships and disciplined spending are emerging as key survival tools in challenging funding environment.

Neuromodulation Is Booming – But Shocks Could Still Come

 
• By Barnaby Pickering

The neuromodulation space is quickly filling with well-funded companies that have demonstrated early signs of success. However, with strategics seemingly unwilling to spend on novel technologies and pharma desperate to maintain its foothold in CNS, these companies will face many challenges.

More from In Vivo

Podcast: The Potential Of AI In Developmental Cell Biology

 
• By David Wild

In this episode, In Vivo speaks with Micha Breakstone, co-founder and CEO of Somite.AI, and Samantha Dale Strasser, VP of strategy, to explore how their techbio is applying foundation models to human cell differentiation.

A Year Of Firsts As Biosimilars Build Momentum In US

 
• By Dave Wallace

In a busy year for US biosimilars, 2025 saw more than a dozen approvals as multiple biologics faced competition for the first time – including Stelara. However, concerns persist over the lack of rivals in development for numerous brands coming off-patent, with a hope that regulatory streamlining can

Pharmatech Funding: What Corporate VCs Actually Want

 
• By David Wild

Corporate venture arms can be powerful growth partners, but founders who don’t take time to understand them risk missing their greatest value.